South Dakota Investment Council Raises Holdings in Illumina, Inc. $ILMN

South Dakota Investment Council boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 54.5% in the 2nd quarter, Holdings Channel reports. The firm owned 32,608 shares of the life sciences company’s stock after buying an additional 11,500 shares during the quarter. South Dakota Investment Council’s holdings in Illumina were worth $3,111,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC increased its holdings in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares in the last quarter. Cullen Frost Bankers Inc. acquired a new stake in Illumina in the 2nd quarter valued at $41,000. Caitong International Asset Management Co. Ltd increased its holdings in Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares in the last quarter. Center for Financial Planning Inc. increased its holdings in Illumina by 42.4% in the 2nd quarter. Center for Financial Planning Inc. now owns 588 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 175 shares in the last quarter. Finally, WPG Advisers LLC acquired a new stake in Illumina in the 1st quarter valued at $58,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on ILMN shares. Daiwa America downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. Citigroup downgraded Illumina from a “hold” rating to a “strong sell” rating and lowered their target price for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Barclays raised their target price on Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research note on Friday. Canaccord Genuity Group raised their target price on Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a research note on Friday. Finally, Morgan Stanley raised their target price on Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $115.00.

Illumina Stock Down 2.9%

NASDAQ:ILMN opened at $119.99 on Tuesday. The company has a market capitalization of $18.44 billion, a price-to-earnings ratio of 15.19, a price-to-earnings-growth ratio of 2.34 and a beta of 1.40. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The stock has a 50-day simple moving average of $98.81 and a 200 day simple moving average of $93.24. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period last year, the firm earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.